| Background:Bcl11b is a transcriptive factor expressed in T cells during their development and on to the matured stage as αβ-T cells, as well as in γδT cells and NKT cells. The molecule has two different main alternative transcripts. It plays a key role in the T cell’s differentiation and proliferation as accumulating in the cells. Loss of its function leads to loss of commitment, of which the outcomes diversify and the cells may apoptosize or proliferate permanently or retrodifferentiate. It was observed in the mice that knock-off of the gene caused vulnerability of manigancies. And also in the hematological tumors developed in mice, LOH and other kinds of expression compromises of bel11b increased. Bcl11b has also been reported in several kinds of hematologic malignancies.In some TALL cases, the expression level increased while in some CLL cases, the gene was epigenetically modified.Thus,its real function in oncogenesis is not explicit because the regulation function is ambiguous. Recently,it has been discovered that the sencond splicing variants as bel11-2was the main functional component. More,loss of expression of the molecule in different developmental stage of T cell ended up with diversified consequances.In immature cells the fate of a T cell was turned to a cytoxicity-competant ITNK cell way. While in adult T cells, loss of function of bcl11b reduced the antigen-induced specific immune-response.Objectives:1To fine the relationship of transcribed bcl11b in peripheral T cells and hematoligic malignancy morbidity.2To find the correlation between the amount of bcl11b and a few of the factors indicating disease severity and prognosis.3To evaluate the prognostic ability of bell lb in patients receiving stem cell graft by following the expression within35days of transplantation.Methods:Take the peripheral blood samples from patients with different blood malignancies and controls, the T cell percentages were examed by flow cytometry, the expression levels of bcl11b were measured by realtime PCR using SYBr Green as the mRNA copies,the data analysis was done by the statistics software SPSSResults: 1The expression level of bclllb alternative splicing transcript2was lower in lymphocytic leukemia, myeloid leukemia, lymphoma, multiple myeloma and myelodysplastic syndrome with statistical significance,which indicates a possible prognostic value. Transcript1was also different compared to the control,but without a statistical significance. The sum of the two transcripts also showed significant differences inmyeloid leukemia and lymphoma,but was barely prognostic usable.2The expression level of bcl11-2lowered in MM patients with x-ray detectable bone lesions or higher DS stage,as well as in CLL patients with higher Rai stage. And also differed in lymphoma patients as to a few of the clinical severity indice. To defiine the predicting ability for AML therapy,further investigation is needed.3Within35days after PBSCT, bclllb expression level was low despite the gradual restore of the blood cell components. The low transcription level and the prognostic value of the molecure are still open to more studies.Conclusions:Expression level of bclllb-2is low in several common hematopoietic malignacies, thus can be utilized as a promising predicting factor. In patients with multiple myeloma and choronic lymphocytic leukemia, lower expression level was observed for those with a poor clinical factor, and hence may serve as a prognostic index. Patients receiving stem cell transplantation have decreased amount of bcl11b mRNA within35days after the operation,which needs further studies. |
PDF Full Text Request